
Cagent Vascular Announces the Launch of Serranator SL-PRO™ for Pedal and Tibial Disease Treatment
Cagent Vascular a leader in the development of cutting-edge serration technology for vessel dilation in endovascular procedures, has unveiled its latest innovation: the Serranator SL-PRO™ PTA Serration Balloon Catheter. This new product represents a significant advancement in the treatment of peripheral artery disease (PAD), particularly in challenging areas such as pedal interventions and tibial disease. The Serranator SL-PRO™ is built on Cagent’s well-established Serration Technology, which has been proven to offer effective and predictable results. It provides clinicians with a state-of-the-art solution designed to tackle complex vascular conditions in the lower extremities.

The Serranator SL-PRO™ balloon catheter is specifically designed for use in areas that are often difficult to treat with traditional devices, particularly the pedal arteries and challenging tibial lesions. This product builds upon the success of previous iterations of the Serranator, which have already demonstrated their effectiveness in various clinical settings. The SL-PRO™ version offers a redesigned platform that enhances the device’s deliverability and trackability, making it easier for physicians to navigate complex vasculature. This ensures better access to areas that may have previously been difficult to reach.
One of the standout features of the Serranator SL-PRO™ is its ability to generate 1,000 times the point force compared to plain balloon angioplasty. This remarkable force significantly enhances the balloon’s ability to create linear, interrupted scoring along the vessel’s endoluminal surface, which results in superior arterial expansion and predictable lumen gain. Furthermore, the balloon’s serration technology operates during slow-and-low balloon inflation, which minimizes the risk of dissection and injury to the artery. This controlled approach ensures optimal treatment while maintaining the integrity of the vessel wall.
Dr. Michael Lichtenberg, a highly regarded expert in vascular medicine and the Chief Medical Officer at the Arnsberg Clinic in Germany, expressed his enthusiasm for the new device. As a seasoned user of the original Serranator technology, Dr. Lichtenberg has witnessed firsthand the significant benefits that the device provides for patients with peripheral artery disease (PAD). His clinical experience with the Serranator has demonstrated the balloon’s ability to achieve substantial lumen gain with a low complication rate, particularly in below-the-knee (BTK) interventions.
“Having used the Serranator in my practice, I have become accustomed to its many advantages,” said Dr. Lichtenberg. “We see excellent lumen gain, a low complication rate, and a 6% BTK vessel recoil rate compared to the much higher 55% recoil seen with traditional plain balloon angioplasty. This low recoil is crucial in ensuring long-term patient outcomes and preventing restenosis.” He continued, “With the introduction of the SL-PRO, we are excited to see how this redesigned platform further improves the deliverability and overall efficacy of the device. We believe it will help us treat more complex disease, including those in the pedal arteries, with even greater success.”
Peripheral artery disease, especially in its more severe forms, often involves occlusions and narrowing of arteries that can be challenging to treat, particularly in the lower extremities. As PAD progresses, it can lead to critical limb ischemia (CLI), a condition that significantly impacts patients’ quality of life and can lead to amputation if left untreated. As PAD worsens, treating disease in the tibial and pedal arteries becomes increasingly difficult, making it a crucial focus for Cagent Vascular. The company’s Serranator technology has proven to be a powerful tool in addressing these issues by enabling physicians to achieve effective and predictable lumen gain in tough-to-treat areas.
Cagent Vascular’s Chairman and CEO, Brian Walsh, emphasized the company’s ongoing commitment to advancing solutions for physicians who are on the front lines of treating PAD and its complications. Walsh stressed that Cagent Vascular is dedicated to providing physicians with the tools they need to effectively treat PAD and improve outcomes for patients suffering from this debilitating disease.
“We are unwavering in our commitment to developing and advancing technologies that can make a real difference in the lives of PAD patients,” said Walsh. “With over 20,000 Serranation procedures already completed and a growing body of clinical evidence, we have seen the positive impact our technology has had in the treatment of PAD. The Serranator SL-PRO™ represents the next evolution of this technology, and we are excited about its potential to treat complex vascular disease in both the tibial and pedal arteries. Now, with the SL-PRO™ catheter, the Serranator product family can effectively treat patients from hip to toe.”
The Serranator SL-PRO™ PTA Serration Balloon Catheter is an FDA-cleared device that uses a proprietary stainless steel micro-serration technology. This technology allows the balloon to create small, interrupted incisions in the arterial walls, facilitating better expansion of the vessel during balloon inflation. This approach contrasts with traditional balloon angioplasty, which relies on the sheer mechanical pressure of the balloon to dilate the vessel. By incorporating serration, the Serranator balloon provides a more controlled and consistent dilation process, which can lead to improved clinical outcomes and a lower risk of complications.
One of the major advantages of using the Serranator SL-PRO™ over traditional balloon angioplasty is the device’s ability to maintain better vessel wall integrity while achieving excellent lumen gain. The technology’s unique mechanism of action means that it is far less likely to cause vessel dissection or damage to the surrounding tissue, which can lead to further complications down the line. The lower rate of vessel recoil, as demonstrated by Dr. Lichtenberg’s clinical experience, also helps ensure long-term success after the procedure. This makes the Serranator SL-PRO™ an ideal tool for treating complex and calcified lesions, especially in the below-the-knee and pedal regions, where traditional treatments have often fallen short.
The 1,000 times increase in point force provided by the Serranator SL-PRO™ is another key feature that sets it apart from conventional devices. The device’s serrated surface is designed to interact with the vessel in a way that enhances its ability to expand, leading to more predictable and controlled lumen gain. This increased point force not only helps with achieving optimal vessel dilation, but it also helps minimize complications such as artery dissection, which is a common concern during angioplasty procedures.
The Serranator SL-PRO™ is a significant advancement in the company’s commitment to improving outcomes for PAD patients and expanding the possibilities of endovascular intervention. This product will help address the growing need for effective treatments in challenging anatomical areas like the pedal and tibial arteries, and it complements Cagent Vascular’s broader portfolio of endovascular tools designed to treat a wide range of vascular conditions.
The success of the Serranator SL-PRO™ is built on a foundation of clinical evidence that continues to grow as more procedures are performed. With over 20,000 Serranation procedures already completed, Cagent Vascular has been able to accumulate invaluable data on the technology’s performance, providing physicians with the confidence they need to incorporate it into their practice. The growing library of clinical evidence supports the effectiveness of Serranator devices in improving patient outcomes and reducing the risks associated with traditional balloon angioplasty.
The launch of the Serranator SL-PRO™ marks a major milestone in the ongoing fight against peripheral artery disease and its most severe forms. With this new product, Cagent Vascular is poised to make an even greater impact in the treatment of PAD, particularly in challenging areas like the pedal and tibial arteries. As the company continues to innovate and expand its product offerings, it remains dedicated to providing healthcare professionals with the tools they need to improve the quality of life for patients suffering from PAD and other vascular conditions.
In conclusion, the Serranator SL-PRO™ PTA Serration Balloon Catheter represents a groundbreaking advancement in the treatment of peripheral artery disease. Designed with precision and built on the success of previous Serranator technologies, this innovative device offers a new level of performance in treating complex vascular lesions. With its ability to achieve predictable and controlled lumen gain while minimizing complications, the Serranator SL-PRO™ has the potential to revolutionize how physicians treat challenging vascular conditions in the lower extremities. Cagent Vascular’s ongoing commitment to advancing endovascular interventions ensures that PAD patients have access to the most effective and cutting-edge therapies available today.